2月7日,石药创新制药股份有限公司发布公告,控股子公司石药集团巨石生物制药有限公司,于近日收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SYS6017的《药物临床试验批准通知书》,将于近期开展临床试验。SYS6017由编码水痘-带状疱疹病毒(varicella-zoster virus,VZV)糖蛋白 E(gE 蛋白)的mRNA 分子包裹于脂质纳米颗粒所构成,适用于预防带状疱疹的感染...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.